This low float China AI stock is squeezing

Today’s big movers inside                                                                                                                                                                                                                                                                                                                                                                                                                 March 06, 2024 *Promoted by Sica Media Good day, 360! Here are our top investing ideas today. These setups look primed! Be the best prepared trader on the Street! FOCUS LIST🔎 IFBD - China related name up 60% in pre after completing reverse split on Monday CELZ - Up over 40% in pre after receiving FDA Orphan Drug Designation for CELZ-101 in key transplantation therapy MRAI - Up over 15% in pre after signing on new client SPOTLIGHT💡 *Promoted by Sica Media Yesterday, I shared this chart on the QQQ with members just to show how violent market moves have been, both up and down… If there is one thing you’ll notice in the chart above… ALL of those moves were predictable if you simply looked for a break above/below my “magical” 20-hour line. Which leads me to my HOT STOCK IDEA: MAIA Biotechnology, Inc. (MAIA). MAIA is a clinical-stage biopharmaceutical company exploring genuinely groundbreaking cancer treatments. [For a detailed breakdown of MAIA’s trial progress and drug pipeline, check out company CEO Vlad Vitoc’s [Letter to Shareholders]( released just yesterday.] What you’ll immediately see is that even with the market carnage yesterday, MAIA started to break out into a “Gamma Trigger” move. (Yeah, there was actually a stock showing some strength in the midst of the wreckage yesterday!) Of course, you never know what will happen in the future, but based on this stock’s moves seen in the past… I think MAIA has the potential to become one of the biggest movers in the entire market today. Whatever you do in trading, make sure you do your due diligence and come to the market with a solid game plan that fits your unique risk tolerance. Never trade with money that you can’t afford to lose.  *Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. HOTLIST🔥 IFBD - China related name up 60% in pre after completing reverse split on Monday Infobird Co., Ltd (IFBD) operates as a software-as-a-service (SaaS) provider of artificial intelligence (AI) enabled customer engagement solutions in the People's Republic of China. IFBD [completed its reverse split]( on Monday March 4 with a float of just 0.85 million shares. The AI related name is in play this morning after being beaten down in recent days. The stock traded up over 60% in the pre-market this morning. The $7.80 area has acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $8.60, $9.90 and then the pre-market high at $10.39. Beyond that, $15 and $20 come into play. Below $7.80, targets to the downside are $7.60, $7, $6.50, $6, and then a gap fill to $5.23. CELZ - Up over 40% in pre after receiving FDA Orphan Drug Designation for CELZ-101 in key transplantation therapy Creative Medical Technology Holdings, Inc. (CELZ) operates in the field of regenerative medicine with a focus on developing novel therapies in immunotherapy, endocrinology, urology, gynecology, and orthopedics. In the pre-market this morning, [the company announced]( that it had received Orphan Drug Designation for CELZ-101, ImmCelz(™). The therapy is aimed at preventing allograft rejection in patients undergoing pancreatic islet cell transplantation. The company stated it is “a significant advancement for individuals dealing with brittle Type 1 diabetes, a condition characterized by extreme fluctuations in blood glucose levels” The stock traded up over 40% in reaction to the news. The $5.40 area has acted as support so far in the pre-market and will be an important level to watch. Above it, targets to the upside are $6, $6.50, $7 and then the pre-market high at $7.60. Beyond that, $8 and $9 come into play. Below $5.40, targets to the downside are $5.14, $5, $4.70, $4.50 and then a gap fill at $4.13. [BULLSEYE UNLIMITED]( Using his Custom Gamma Trigger and 20+ years of trading experience, Jeff’s been on a TEAR in 2024…  Like the potential of Jeff’s trade plan for DECK! Note: Trading is hard, results not guaranteed and should not be expected to be replicated typically. Learn How to Use the GAMMA TRIGGER [Get Jeff’s Top 3 Trade Plans/Day!]( CODE BULLSEYE FOR $200 OFF (HIT APPLY) MRAI - Up over 15% in pre after signing on new client Marpai, Inc. (MRAI) is a technology-driven healthcare payer, that focuses on providing services to the self-insured employer market in the United States and Israel. In the after-hours yesterday, [the company announced]( an “off-cycle” new client agreement. MRAI states it has signed a three-year agreement to provide healthcare benefit services to a regional organization based in the southeast. The agreement commenced this month, and it is expected to bring at least 20,000 households by the end of 2024. The stock traded up over 50% in the after-hours before pulling back to around 15% higher in the pre-market this morning. The $1.66 level found some buyers in the pre-market after a pullback. Above it, targets to the upside are $1.80, $1.90, $2, $2.20, $2.40 and then the pre-market high at $2.62. Below $1.66, targets to the downside are $1.60 and then a gap fill at $1.53. MARKET NEWS 📰 P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull DISCLOSURES *PAID ADVERTISEMENT. Raging Bull has currently been paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on for a one day marketing program. Raging Bull has previously been paid fourteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on November 15 through November 18, 2023. Raging Bull has previously been paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on October 12 through October 13, 2023. The third party, Company, or their affiliates may own and likely wish to liquidate shares of the Company at or near the time you receive this advertisement, which has the potential to hurt share prices. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of MAIA Biotechnology, Inc, increased trading volume, and possibly an increased share price of MAIA Biotechnology, Inc’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in MAIA Biotechnology, Inc, though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https: // www. Sec. gov/ edgar/searchedgar /companysearch TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360wallstreet 62 Calef Hwy. #233 Lee, NH 03861, United States of America